Esperion Therapeutics Statistics
Total Valuation
ESPR has a market cap or net worth of $554.46 million. The enterprise value is $1.07 billion.
Important Dates
The next estimated earnings date is Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ESPR has 201.62 million shares outstanding. The number of shares has increased by 34.63% in one year.
| Current Share Class | 201.62M |
| Shares Outstanding | 201.62M |
| Shares Change (YoY) | +34.63% |
| Shares Change (QoQ) | +0.72% |
| Owned by Insiders (%) | 0.92% |
| Owned by Institutions (%) | 51.75% |
| Float | 199.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 28.65 |
| PS Ratio | 2.01 |
| Forward PS | 1.34 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.15
| Current Ratio | 1.15 |
| Quick Ratio | 0.65 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -6.34% |
| Return on Invested Capital (ROIC) | -11.75% |
| Return on Capital Employed (ROCE) | -73.41% |
| Revenue Per Employee | $881,990 |
| Profits Per Employee | -$342,178 |
| Employee Count | 304 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 1.45 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +54.49% in the last 52 weeks. The beta is 0.89, so ESPR's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | +54.49% |
| 50-Day Moving Average | 1.93 |
| 200-Day Moving Average | 1.67 |
| Relative Strength Index (RSI) | 71.40 |
| Average Volume (20 Days) | 6,245,048 |
Short Selling Information
The latest short interest is 22.35 million, so 11.08% of the outstanding shares have been sold short.
| Short Interest | 22.35M |
| Short Previous Month | 22.64M |
| Short % of Shares Out | 11.08% |
| Short % of Float | 11.19% |
| Short Ratio (days to cover) | 4.33 |
Income Statement
In the last 12 months, ESPR had revenue of $268.13 million and -$104.02 million in losses. Loss per share was -$0.53.
| Revenue | 268.13M |
| Gross Profit | 123.96M |
| Operating Income | -35.45M |
| Pretax Income | n/a |
| Net Income | -104.02M |
| EBITDA | -35.34M |
| EBIT | -35.45M |
| Loss Per Share | -$0.53 |
Full Income StatementBalance Sheet
The company has $86.06 million in cash and $598.18 million in debt, giving a net cash position of -$512.12 million or -$2.54 per share.
| Cash & Cash Equivalents | 86.06M |
| Total Debt | 598.18M |
| Net Cash | -512.12M |
| Net Cash Per Share | -$2.54 |
| Equity (Book Value) | -433.51M |
| Book Value Per Share | -2.17 |
| Working Capital | 43.80M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$124.33 million and capital expenditures -$167,000, giving a free cash flow of -$124.49 million.
| Operating Cash Flow | -124.33M |
| Capital Expenditures | -167,000 |
| Free Cash Flow | -124.49M |
| FCF Per Share | -$0.62 |
Full Cash Flow StatementMargins
Gross margin is 46.23%, with operating and profit margins of -13.22% and -38.80%.
| Gross Margin | 46.23% |
| Operating Margin | -13.22% |
| Pretax Margin | -38.80% |
| Profit Margin | -38.80% |
| EBITDA Margin | -13.18% |
| EBIT Margin | -13.22% |
| FCF Margin | n/a |
Dividends & Yields
ESPR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -34.63% |
| Shareholder Yield | -34.63% |
| Earnings Yield | -18.76% |
| FCF Yield | -22.45% |
Analyst Forecast
The average price target for ESPR is $6.50, which is 136.36% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.50 |
| Price Target Difference | 136.36% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 18.76% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ESPR has an Altman Z-Score of -5.81 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.81 |
| Piotroski F-Score | 1 |
